Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases

Basma Hossam Abdelmonem1,2, Lereen T Kamal1, Lilian Waheed Wardy3,4

  • 1Institute of Global Health and Human Ecology, School of Sciences and Engineering, The American University in Cairo, New Cairo, Egypt.

Frontiers in Oncology
|March 25, 2025
PubMed

Insights

Non-coding RNAs (ncRNAs) are key regulators in gene expression, impacting cancer and inflammatory diseases. Research highlights their potential as biomarkers and therapeutic targets for personalized medicine and diagnostics.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • Non-coding RNAs (ncRNAs) regulate gene expression at transcriptional, post-transcriptional, and epigenetic levels.
  • Aberrant ncRNA expression is linked to cancer progression, metastasis, and therapeutic response.
  • ncRNAs interact with critical cellular pathways (MAPK, Wnt, PI3K/AKT/mTOR) influencing proliferation, apoptosis, and immune responses.

Purpose of the Study:

  • To review the roles of ncRNAs as biomarkers and therapeutic targets in cancer and inflammatory diseases.
  • To explore ncRNA mechanisms in gene regulation and their diagnostic/therapeutic implications.
  • To assess the potential of ncRNA-based diagnostics and targeted therapies.

Main Methods:

  • Comprehensive literature review of PubMed and Google Scholar (2014-2025).
  • Inclusion of peer-reviewed studies on ncRNA roles in cancer and inflammatory diseases.
  • Exclusion of non-English, non-peer-reviewed, and inconclusive studies.

Main Results:

  • ncRNAs (microRNAs, long non-coding RNAs, circular RNAs) are crucial for gene regulation.
  • ncRNA expression patterns offer potential for non-invasive diagnostics and targeted therapies.
  • RNA-based therapeutics (anti-miRNAs, miRNA mimics) show promise, with ongoing development to address stability and delivery challenges.

Conclusions:

  • ncRNAs represent significant biomarkers and therapeutic targets for cancer and inflammatory diseases.
  • Precision medicine advancements leverage ncRNA profiling for individualized treatments and improved patient outcomes.
  • Further research into ncRNA delivery and stability is crucial for clinical translation.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.1K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
62.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.2K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K